<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Clinical research Drug discovery Pharmaceutical industry Food and Drug Administration Organochlorides Biomarker Center for Drug Evaluation and Research Critical Path Institute Drug development Medicine Pharmacology Pharmaceutical sciences |
Add to Reading List |
Program, Ides of March 2012 | CENTER FOR DRUG EVALUATION AND RESEARCH DRUG SAFETY PRIORITIES 2017DocID: 1ueGS - View Document |
| CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 208573Orig1s000 SUMMARY REVIEWDocID: 1t19G - View Document |
| CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022526Orig1s000 SUMMARY REVIEWDocID: 1sZi5 - View Document |
| MEMORANDUM DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCHDocID: 1sPXO - View Document |
| Abstract # 2639 Enhanced (Q)SAR Models for Prediction Rodent Carcinogenicity Naomi L. Kruhlak1, Dongyu Guo1, Kevin P. Cross2, Lidiya Stavitskaya1 FDA Center for Drug Evaluation and Research (CDER), 10903 New Hampshire ADocID: 1swgc - View Document |